ベシフロキサシン塩酸塩
ベシフロキサシン塩酸塩 物理性質(zhì)
- 融點(diǎn) :
- >210°C (dec.)
- 貯蔵溫度 :
- Inert atmosphere,2-8°C
- 溶解性:
- メタノール（わずかに、加熱、超音波処理）、水（わずかに、加熱、超音波処理）
- 外見(jiàn) :
- 個(gè)體
- 色:
- オフホワイトからライトベージュ
- InChI:
- InChI=1/C19H21ClFN3O3.ClH/c20-15-16-12(18(25)13(19(26)27)9-24(16)11-4-5-11)7-14(21)17(15)23-6-2-1-3-10(22)8-23;/h7,9-11H,1-6,8,22H2,(H,26,27);1H/t10-;/s3
- InChIKey:
- PMQBICKXAAKXAY-MEQOOBBNNA-N
- SMILES:
- ClC1C(N2CCCC[C@@H](N)C2)=C(F)C=C2C(=O)C(C(=O)O)=CN(C3CC3)C=12.Cl |&1:8,r|
安全性情報(bào)
- リスクと安全性に関する聲明
- 危険有害性情報(bào)のコード(GHS)
ベシフロキサシン塩酸塩 価格
もっと(5)
| メーカー |
製品番號(hào) |
製品説明 |
CAS番號(hào) |
包裝 |
価格 |
更新時(shí)間 |
購(gòu)入 |
|
富士フイルム和光純薬株式會(huì)社(wako)
|
W01TRCB319000 |
ベシフロキサシン塩酸塩
Besifloxacin Hydrochloride |
405165-61-9 |
10mg |
￥26400 |
2024-03-01 |
購(gòu)入 |
|
富士フイルム和光純薬株式會(huì)社(wako)
|
W01TRCB319000 |
ベシフロキサシン塩酸塩
Besifloxacin Hydrochloride |
405165-61-9 |
25mg |
￥50400 |
2024-03-01 |
購(gòu)入 |
|
富士フイルム和光純薬株式會(huì)社(wako)
|
W01TRCB319000 |
ベシフロキサシン塩酸塩
Besifloxacin Hydrochloride |
405165-61-9 |
50mg |
￥95100 |
2024-03-01 |
購(gòu)入 |
|
富士フイルム和光純薬株式會(huì)社(wako)
|
W01TRCB319000 |
ベシフロキサシン塩酸塩
Besifloxacin Hydrochloride |
405165-61-9 |
100mg |
￥161200 |
2023-06-01 |
購(gòu)入 |
|
富士フイルム和光純薬株式會(huì)社(wako)
|
W01TRCB319000 |
ベシフロキサシン塩酸塩
Besifloxacin Hydrochloride |
405165-61-9 |
200mg |
￥322600 |
2023-06-01 |
購(gòu)入 |
ベシフロキサシン塩酸塩 化學(xué)特性,用途語(yǔ),生産方法
効能
抗菌薬, 核酸合成阻害薬
説明
Besifloxacin is a new fluoroquinolone antibacterial for ophthalmic
use. It is indicated for the treatment of bacterial conjunctivitis, one of
the most common ocular infections encountered in the primary care
setting. Although the previously marketed fluoroquinolones ciprofloxacin, levofloxacin, ofloxacin, gatifloxacin, and moxifloxacin have been
widely used to treat bacterial conjunctivitis, their continued utility is
hampered by the emergence of resistance among key ocular isolates
such as Staphylococcus aureus. Besifloxacin is the first
fluoroquinolone developed exclusively for topical ophthalmic use.
Unlike the previously marketed fluoroquinolones, besifloxacin has not
been used systemically and is not in development as a systemic agent. Its
exclusive indication as a topical agent is expected to reduce the overall
environmental exposure of bacteria to besifloxacin, which may contribute to a lower risk for the emergence of bacterial resistance. Fluoroquinolones derive their antibacterial activity via inhibition of two essential
bacterial enzymes, DNA gyrase and topoisomerase IV, which regulate
processes of DNA replication. Besifloxacin inhibits DNA gyrase and topoisomerase IV from Streptococcus pneumoniae (IC50 = 1 and 0.4 mg/ L, respectively) and Escherichia coli (IC50 = 1 and 10 mg/L, respectively).
化學(xué)的特性
Pale Yellow Solid
使用
Besifloxacin HCl is a fourth-generation fluoroquinolone antibiotic
副作用
The most common adverse event reported in patients treated with besifloxacin ophthalmic suspension was conjunctival redness. Other less common adverse events were blurred vision, eye pain, eye irritation, eye pruritus, and headache.
ベシフロキサシン塩酸塩 上流と下流の製品情報(bào)
原材料
準(zhǔn)備製品
ベシフロキサシン塩酸塩 生産企業(yè)
Global( 259)Suppliers
ベシフロキサシン塩酸塩 スペクトルデータ(1HNMR)
405165-61-9(ベシフロキサシン塩酸塩)キーワード:
- 405165-61-9
- (R)-7-(3-AMinohexahydro-1H-azepin-1-yl)-8-chloro-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-quinolin-3-carboxylic acid HCl
- 3-Quinolinecarboxylic acid, 7-[(3R)-3-aMinohexahydro-1H-azepin-1-yl]-8-chloro-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-, Monohydrochloride (9CI)
- (R)-7-(3-aMinoazepan-1-yl)-8-chloro-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid hydrochloride
- Unii-7506A6J57t
- (R)-7-(3-Aminohexahydro-1H-azepin-1-yl)-8-chloro-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid hydrochloride
- Besifloxacin hydrochloride
- Becifloxacin Hydrochloride
- BESIFLOXACIN HCL INTERMEDIATES
- Hydrochloric Besifloxacin
- 3-Quinolinecarboxylic acid, 7-[(3R)-3-aminohexahydro-1H-azepin-1-yl]-8-chloro-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-, hydrochloride (1:1)
- Besifloxacin HCl (Besivance)
- Besifloxacin hydrochloride, >=98%
- 7-[(3R)-3-AMinohexahydro-1H-azepin-1-yl]-8-chloro-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic Acid Hydrochloride
- 7-[(3R)-3-AMinohexahydro-
- Besifloxacin HC
- CS-781
- Besifloxacin hydrochloride (405165-61-9)
- Besivance hydrochloride
- BOL-303224-A
- Besifloxacin hydrochloride USP/EP/BP
- Besifloxacin Hydrochloride (Contains ~15% Inorganics)
- Besifloxacin Hcl Intermediate
- 7-(3-aminoazepan-1-yl)-8-chloro-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid hydrochloride
- Pranoprofer
- 7-[(3R)-3-aminoazepan-1-yl]-8-chloro-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid hydrochloride
- Besifloxacin Hydrochloride, 10 mM in DMSO
- Besifloxacin HCl - Bio-X ?
- Besifloxacin HCl
- ベシフロキサシン塩酸塩